Business Context and Reporting Period
Company: Organogenesis Holdings Inc. (formerly Avista Healthcare Public Acquisition Corp. or "AHPAC")
Reporting Date: December 10, 2018
Event: Consummation of a business combination (SPAC merger) with Organogenesis Inc. AHPAC redomesticated from the Cayman Islands to Delaware and changed its name to Organogenesis Holdings Inc. ("ORGO"). Organogenesis Inc. became a wholly-owned subsidiary of ORGO.
Listing: ORGO common stock and warrants began trading on NASDAQ under symbols "ORGO" and "ORGOW", respectively.
Key Financial Metrics and Capital Structure
Capitalization: Approximately 91,989,961 shares of common stock outstanding immediately following the Business Combination.
Exchange Ratio: Each share of Organogenesis Common Stock was converted into 2.03 shares of ORGO Class A common stock.
Warrants and Options: Existing Organogenesis warrants and options were converted into replacement warrants and assumed options for ORGO stock, adjusted by the exchange ratio.
Financial Statements: The filing incorporates by reference Organogenesis audited financial statements for years ended Dec 31, 2016 and 2017, and unaudited statements for the nine months ended Sept 30, 2018. Specific revenue, profit, cash flow, or debt figures are not explicitly stated in this 8-K text but are referenced in attached exhibits (99.1, 99.2, 99.4).
Material Changes and Ownership Structure
- Control Change: The "Controlling Entities" (Alan A. Ades, Albert Erani, Glenn H. Nussdorf, and affiliates) hold approximately 73.4% of the outstanding shares, effectively controlling the company.
- Major Shareholders:
- Organo PFG and affiliated entities: 38.0%
- Avista Capital Partners IV (PIPE Investors): 16.9%
- All directors and executive officers as a group: 69.6%
- Corporate Governance: A new Board of Directors was elected, consisting of eight members. The Board appointed an Audit Committee and new executive officers, including Gary S. Gillheeney, Sr. as CEO and Timothy M. Cunningham as CFO.
- Accounting Firm Change: Marcum LLP was dismissed as the independent registered public accounting firm. RSM US LLP was engaged effective December 10, 2018.
Agreements and Governance
- Registration Rights: An Amended and Restated Registration Rights Agreement was entered into with PIPE Investors and Restricted Stockholders.
- Stockholders Agreement: PIPE Investors (holding >7.5%) have the right to designate one director nominee and one board observer.
- Controlling Stockholders Agreement: Provides the Controlling Entities the right to nominate four directors to the Board.
- Equity Incentive Plan: The 2018 Equity Incentive Plan was approved, reserving 9,198,996 shares for issuance.
Outlook, Risks, and Contingencies
Forward-Looking Statements: The filing includes standard disclaimers regarding expectations for future financial performance, integration benefits, and market expansion. Actual results may differ due to risks including legal proceedings, NASDAQ listing status, integration challenges, and reimbursement rates from government health programs.
Legal Proceedings: ORGO is party to certain legal actions arising from normal business operations; management believes none will have a material effect on operations or financial condition.
Dividends: ORGO does not anticipate declaring cash dividends in the foreseeable future, intending to retain earnings for operations.
Investor Verification Checklist
- Pro Forma Financials: Review Exhibit 99.4 for unaudited pro forma combined financial information to understand the post-merger financial position.
- Historical Performance: Examine Exhibit 99.1 and 99.2 for Organogenesis' historical revenue, net loss, and cash burn rates prior to the merger.
- Debt Obligations: Review the Credit Agreement (Exhibit 10.24) and related amendments to understand outstanding debt, covenants, and repayment terms.
- Concentration Risk: Verify the impact of the Controlling Entities holding 73.4% of voting power on minority shareholder rights and future corporate decisions.
- Warrant Terms: Confirm the exercise price and terms of the replacement warrants issued to former Organogenesis warrant holders.